For individuals with risk factors for recurrence, the CANMAT 2016 Depression guidelines recommend that treatment be extended to 2 years or more after achieving remission of symptoms. These factors include: frequent and/or recurrent episodes, severe episodes (psychosis, severe impairment, suicidality), ...
International datasets are being shared from multi-ethnic community populations, first episode and recurrent MDD, which are medication-free, in a current depressive episode with prospective longitudinal treatment outcomes and in remission. Neuroimaging data consist of de-identified, individual, structural MR...
May be used as first-line in mild-moderate depression When is Vagal Nerve Stimulation (VNS) used? what are side effects? ADJUNCTIVE treatment for CHRONIC, recurrent depression (lasting 2 years, not responding to >4 trials of ADs) in patients >18 years oldSide effects: voice changes, throat...
Using a HAMD-17 total score of ≤ 7 as the criterion for remission, the remission rates of both groups at different visit points were compared. The findings suggested that the remission rates for depressive symptoms in both groups exhibited an incremental trend across the four post-baseline...
, whereas other studies found lower hippocampal volumes only in adults with an age of onset >3056 or no differences in hippocampal volume between adults with an adolescent versus adult age of onset of MDD57. Because only about half (57%) of the adolescent-onset patients had a recurrent ...
The article discusses research which investigated the effectiveness of venlafaxine in preventing recurrent episodes of depression. It references a study by M. B. Keller and colleagues published in the December 2007 issue of "Biological Psychiatry." The research has found that extended-release ...
Because MDD is a recurrent disorder, it is important to understand the molecular mechanisms underlying not only the symptomatic phase of the disease but also a state of temporary remission. Indeed, molecular changes associated with the application of pharmacotherapy at the remission stage are currently...